UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest reported): February 520, 2025

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-40089	59-3691650
(State or other jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification Number)

11120 NE 2nd Street, Suite 100, Bellevue, WA 98004

(Address of principal executive offices)

(206) 617-9797

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed, on November 7, 2024, Robert Mattacchione resigned as Chief Executive Officer of Novo Integrated Sciences, Inc. (the “Company”), effective 90 days following the notification date (i.e. effective February 5, 2025). ~~Thereafter~~Also as previously disclosed, on February 5, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to February 20, 2025 in order to allow a more efficient transition for the Company and to appropriately address the vacant Chief Executive Officer position ensuring the least amount of disruption as a result of the executive change.

Thereafter, ~~Mr.~~on ~~Mattacchione~~February ~~intends~~20, to2025, ~~continue to serve as (i)~~ the Company’s ~~Chairman of the Board,~~ and ~~(ii)~~Mr. ~~Chairman~~Mattacchione ofagreed ~~Novo~~to ~~Healthnet~~extend ~~Limited, a~~the ~~wholly~~effective ~~owned~~date ~~subsidiary~~ of ~~the Company.~~ Mr. Mattacchione’s resignation ~~was~~to no ~~not~~later athan ~~result~~March of7, ~~any~~2025, ~~disagreement~~in ~~with~~order to provide the Company onthe ~~any~~necessary ~~matter~~time ~~relating~~ to ~~the~~complete ~~Company’s~~an ~~operations,~~efficient ~~policies~~transition of the Chief Executive orOfficer ~~practices~~position.

Following Mr. Mattacchione’s departure as Chief Executive Officer, Mr. Mattacchione intends to continue to serve as (i) the Company’s Chairman of the Board, and (ii) Chairman of Novo Healthnet Limited, a wholly owned subsidiary of the Company. Mr. Mattacchione’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Novo Integrated Sciences, Inc.
Dated: February 11, 2025	By:	/s/ Robert Mattacchione
Dated: February 25, 2025	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

Filing Compare · Novo Integrated Sciences, Inc.